

# TriLink BioTechnologies Analytical Services

Analytical testing is a critical component of every manufacturing program. As a CDMO with an ISO 9001:2015 certification and ICH Q7 Section 19 compliant quality system, we understand that successful biotherapeutic development and manufacturing are supported by comprehensive testing. We offer unparalleled expertise in phase-appropriate method development and analytical testing to further support your mRNA, plasmid, small molecule and oligonucleotide manufacturing process.

## Accelerate Your Product Development with Optimized Testing Services

With over 20 years of experience, we understand your analytical objectives from process development (PD) to scale-up and cGMP manufacturing. TriLink has developed extensive capabilities in **custom method development** and **analytical testing** to ensure a high quality manufacturing process. We work with you to ensure effective method development that meets your objectives at each stage of product development.



### Plasmid

#### Active Moiety Quantification:

- Concentration and Purity (UV Spec), % Supercoiled

#### Identification:

- Sequencing, Restriction Digest Pattern

#### Safety (Microbial):

- Endotoxin, Bioburden

#### Impurity Quantification:

- Residual Protein, Residual gDNA, Isoform Analysis & % RNA (HPLC)

#### Product Characterization:

- Appearance



### Oligonucleotide

#### Active Moiety Quantification:

- HPLC, Concentration (UV-Vis)

#### Identification:

- MS, Retention Time

#### Purity:

- IP-RP HPLC, AX-HPLC

#### Safety (Microbial):

- Endotoxin, Bioburden

#### Impurity Quantification:

- Residual Solvents, ICP-MS

#### Product Characterization:

- Karl Fischer, Thermal Properties [Solution], NMR, Dynamic Vapor Sorption [Lyophilized]



### mRNA

#### Active Moiety Quantification:

- Concentration

#### Identification:

- Sanger Sequencing, PCR, Length, *In Vitro* Translation, RNase Digestion, Analytical Transcription

#### Safety (Microbial):

- Endotoxin, Bioburden, Mycoplasma

#### Impurity Quantification:

- Residual Protein, Residual DNA, Residual Solvents

#### Qualitative Assessment:

- Residual dsRNA, Residual Protein, Agarose Gel, DNase and RNase Detection

#### Product Characterization:

- Appearance, pH, Osmolality, Conductivity, Poly A Tail Length, Capping Efficiency, Integrity



### NTPs, CleanCap® and Other Cap Analogs

#### Active Moiety Quantification:

- Concentration (UV-Vis)

#### Identification:

- MS, <sup>1</sup>H NMR

#### Purity:

- IP-RP HPLC, AX-HPLC, <sup>31</sup>P NMR

#### Safety (Microbial):

- Endotoxin, Bioburden

#### Qualitative Assessment:

- DNase and RNase Detection, Transcription Functional Test

#### Product Characterization:

- Conductivity, pH

Products containing CleanCap technology are for research use only. License is required for commercial use of CleanCap and CleanCap Products. For license restrictions and patent(s) information, refer to <https://www.trilinkbiotech.com/legal-notices>